FDA Approves Dacomitinib for Frontline EGFR+ NSCLC

September 28, 2018 – The FDA has approved dacomitinib for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations, according to Pfizer, the manufacturer of the pan-human EGFR tyrosine kinase inhibitor (TKI). The approval is based on the phase III ARCHER 1050 trial, in which dacomitinib reduced the risk of disease progression or death by more than 40% and resulted in … (leggi tutto)